(EN) The specification provides compositions for ophthalmic or otolaryngological anti-inflammatory use comprising: (A) a corticosteroid having a particle size of 0.1 to 30 microns in diameter in an amount of about 0.2 to 2% by weight; (B) a nonionic polymer in an aqueous medium; and (C) a nonionic surface active agent in an amount sufficient to retain the corticosteroid and nonionic polymer in suspension. (D) a nonionic tonicity agent in an amount sufficient to achieve isotonicity, wherein the molar ratio of (A) : (B) : (C) is about 1:0.1:0.05 to 1:20:1. The corticosteroid is selected from the group consisting of soft steroids having anti-inflammatory activity. The corticosteroid is preferably loteprednol etabonate present in an amount of about 0.5 and 1% by weight. The nonionic polymer is a water soluble polymer selected from the group consisting of polyvinylpyrrolidone, polyvinyl alcohol, dextrin and cyclodextrin and is present in an amount of about 0.2 to 2% by weight. The preferred nonionic polymer is polyvinylpyrrolidone present in an amount of about 0.4 to 1% by weight. The nonionic surface active agent is preferably tyloxapol and is present in an amount of about 0.1 to 0.6% by weight. The nonionic tonicity agent is a nonionic diol, preferably glycerol or mannitol, present in an amount of about 1.5 to 4% by weight.
